The impact of Niacin on PCSK9 levels in vervet monkeys (Chlorocebus aethiops)
Loading...
Date
2020
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
University of the Western Cape
Abstract
Cardiovascular diseases (CVDs) such as ischaemic heart diseases, heart failure and stroke
remain a major cause of death globally. Various deep-rooted factors influence CVD
development; these include but are not limited to elevated blood lipids, high blood pressure,
obesity and diabetes. A considerable number of proteins are involved directly and indirectly in
the transport, maintenance and elimination of plasma lipids, including high and low-density
lipoprotein cholesterol (HDL-C and LDL-C). There are several mechanisms involved in the
removal of LDL particles from systemic circulation. One such mechanism is associated with
the gene that encodes proprotein convertase subtilisin/kexin type 9 (PCSK9), which has
become an exciting therapeutic target for the reduction of residual risk of CVDs. Currently,
statins are the mainstay treatment to reduce LDL-C, and a need exists to further develop more
effective LDL-C-lowering drugs that might supplement statins.
Description
Magister Pharmaceuticae - MPharm
Keywords
Atherosclerosis, Cardiovascular disease (CVD), High-density lipoprotein (HDL), Lipids, Low-density lipoprotein (LDL)